PDF(Pubmed)
Abstract：
BACKGROUND: Pancreatic cancer is a challenging disease, often requiring invasive procedures for diagnosis. Reliable tumour markers are essential for ensuring early detection and better patient outcomes. Although Carbohydrate Antigen 19-9 is the most commonly used marker, it is marred by low predictive accuracy and high false positivity. Carcino Embryonic Antigen also has limited practical use. A novel antigen, Cytokeratin fragment 21-1, is gaining significance for its diagnostic value in various tumours.
METHODS: This prospective study aimed to evaluate the potential of Cytokeratin fragment 21-1 in comparison with Carbohydrate Antigen 19-9 and Carcino Embryonic Antigen in diagnosing pancreatic cancer. From January 2016 to December 2019, 45 patients with confirmed pancreatic ductal adenocarcinoma were included in this cross-sectional study.
RESULTS: Carbohydrate Antigen 19-9 was raised in 22 patients, Carcino Embryonic Antigen was elevated in 17, and Cytokeratin fragment 21-1 was elevated in 30 cases. Carbohydrate Antigen 19-9 was found to be elevated in the presence of jaundice. Both Carbohydrate Antigen 19-9 and Cytokeratin fragment 21-1 had good correlation with stage of cancer, while Carcino Embryonic Antigen had very minimal correlation.
CONCLUSIONS: In this study, Cytokeratin fragment 21-1 was elevated in a higher number of cases than Carbohydrate Antigen 19-9 and Carcino Embryonic Antigen. Both Cytokeratin fragment 21-1 and Carbohydrate Antigen 19-9 correlated well with cancer stage. Also Cytokeratin fragment 21-1 was not affected by jaundice, unlike Carbohydrate Antigen 19-9. Therefore, Cytokeratin fragment 21-1 has the potential to be an effective individual tumour marker in pancreatic cancer.
METHODS: This prospective study aimed to evaluate the potential of Cytokeratin fragment 21-1 in comparison with Carbohydrate Antigen 19-9 and Carcino Embryonic Antigen in diagnosing pancreatic cancer. From January 2016 to December 2019, 45 patients with confirmed pancreatic ductal adenocarcinoma were included in this cross-sectional study.
RESULTS: Carbohydrate Antigen 19-9 was raised in 22 patients, Carcino Embryonic Antigen was elevated in 17, and Cytokeratin fragment 21-1 was elevated in 30 cases. Carbohydrate Antigen 19-9 was found to be elevated in the presence of jaundice. Both Carbohydrate Antigen 19-9 and Cytokeratin fragment 21-1 had good correlation with stage of cancer, while Carcino Embryonic Antigen had very minimal correlation.
CONCLUSIONS: In this study, Cytokeratin fragment 21-1 was elevated in a higher number of cases than Carbohydrate Antigen 19-9 and Carcino Embryonic Antigen. Both Cytokeratin fragment 21-1 and Carbohydrate Antigen 19-9 correlated well with cancer stage. Also Cytokeratin fragment 21-1 was not affected by jaundice, unlike Carbohydrate Antigen 19-9. Therefore, Cytokeratin fragment 21-1 has the potential to be an effective individual tumour marker in pancreatic cancer.
摘要：
背景：胰腺癌是一种具有挑战性的疾病，通常需要侵入性诊断程序。可靠的肿瘤标志物对于确保早期发现和更好的患者预后至关重要。虽然碳水化合物抗原19-9是最常用的标记，它受到低预测准确性和高假阳性的损害。Carcino胚胎抗原也具有有限的实际用途。一种新型抗原，细胞角蛋白片段21-1因其在各种肿瘤中的诊断价值而具有重要意义。
方法：这项前瞻性研究旨在评估细胞角蛋白片段21-1与碳水化合物抗原19-9和Carcino胚胎抗原相比在诊断胰腺癌中的潜力。从2016年1月至2019年12月，45例确诊的胰腺导管腺癌患者纳入本横断面研究。
结果：22例患者出现碳水化合物抗原19-9升高，癌胚抗原升高17例，细胞角蛋白片段21-1升高30例。发现碳水化合物抗原19-9在黄疸存在下升高。糖抗原19-9和细胞角蛋白片段21-1与癌症分期有良好的相关性，而Carcino胚胎抗原的相关性很小。
结论：在这项研究中，细胞角蛋白片段21-1在比碳水化合物抗原19-9和Carcino胚胎抗原更多的病例中升高。细胞角蛋白片段21-1和碳水化合物抗原19-9均与癌症分期密切相关。此外，细胞角蛋白片段21-1不受黄疸的影响，不同于碳水化合物抗原19-9。因此,细胞角蛋白片段21-1有可能成为胰腺癌中有效的个体肿瘤标志物。
方法：这项前瞻性研究旨在评估细胞角蛋白片段21-1与碳水化合物抗原19-9和Carcino胚胎抗原相比在诊断胰腺癌中的潜力。从2016年1月至2019年12月，45例确诊的胰腺导管腺癌患者纳入本横断面研究。
结果：22例患者出现碳水化合物抗原19-9升高，癌胚抗原升高17例，细胞角蛋白片段21-1升高30例。发现碳水化合物抗原19-9在黄疸存在下升高。糖抗原19-9和细胞角蛋白片段21-1与癌症分期有良好的相关性，而Carcino胚胎抗原的相关性很小。
结论：在这项研究中，细胞角蛋白片段21-1在比碳水化合物抗原19-9和Carcino胚胎抗原更多的病例中升高。细胞角蛋白片段21-1和碳水化合物抗原19-9均与癌症分期密切相关。此外，细胞角蛋白片段21-1不受黄疸的影响，不同于碳水化合物抗原19-9。因此,细胞角蛋白片段21-1有可能成为胰腺癌中有效的个体肿瘤标志物。
